• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Transformation into large-cell neuroendocrine carcinoma associated with acquired resistance to erlotinib in nonsmall cell lung cancer.

作者信息

Lim Jeong Uk, Woo In Sook, Jung Yun Hwa, Byeon Jae Ho, Park Chan Kwon, Kim Tae Jung, Kim Hyo Rim

机构信息

Division of Hematology and Oncology, Department of Internal Medicine, Yeouido St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.

Division of Pulmonology, Department of Internal Medicine, Yeouido St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.

出版信息

Korean J Intern Med. 2014 Nov;29(6):830-3. doi: 10.3904/kjim.2014.29.6.830. Epub 2014 Oct 31.

DOI:10.3904/kjim.2014.29.6.830
PMID:25378985
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4219976/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f2e8/4219976/119ed4936172/kjim-29-830-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f2e8/4219976/0915b00482bf/kjim-29-830-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f2e8/4219976/bbea2fcc8db8/kjim-29-830-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f2e8/4219976/119ed4936172/kjim-29-830-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f2e8/4219976/0915b00482bf/kjim-29-830-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f2e8/4219976/bbea2fcc8db8/kjim-29-830-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f2e8/4219976/119ed4936172/kjim-29-830-g003.jpg

相似文献

1
Transformation into large-cell neuroendocrine carcinoma associated with acquired resistance to erlotinib in nonsmall cell lung cancer.非小细胞肺癌中与厄洛替尼获得性耐药相关的向大细胞神经内分泌癌的转化
Korean J Intern Med. 2014 Nov;29(6):830-3. doi: 10.3904/kjim.2014.29.6.830. Epub 2014 Oct 31.
2
Successful Treatment of Non-Small Cell Lung Cancer With Erlotinib Throughout Pregnancy.厄洛替尼全程治疗非小细胞肺癌合并妊娠成功案例
JAMA Oncol. 2015 Sep;1(6):838-40. doi: 10.1001/jamaoncol.2015.1300.
3
Molecular selection trumps clinical selection.分子选择胜过临床选择。
J Clin Oncol. 2011 Jul 20;29(21):2843-4. doi: 10.1200/JCO.2011.35.9208. Epub 2011 Jun 13.
4
First case of A859T epidermal growth factor receptor mutation responding to erlotinib.首例对厄洛替尼有反应的A859T表皮生长因子受体突变病例。
J Thorac Oncol. 2011 Mar;6(3):639-40. doi: 10.1097/JTO.0b013e3182037c0c.
5
Large-cell neuroendocrine carcinoma with epidermal growth factor receptor mutation: possible transformation of lung adenocarcinoma.伴有表皮生长因子受体突变的大细胞神经内分泌癌：肺腺癌可能的转化形式
Respirology. 2012 Nov;17(8):1275-7. doi: 10.1111/j.1440-1843.2012.02258.x.
6
High-dose erlotinib for refractory brain metastases in a patient with relapsed non-small cell lung cancer.高剂量厄洛替尼用于复发非小细胞肺癌患者的难治性脑转移
J Thorac Oncol. 2011 Mar;6(3):653-4. doi: 10.1097/JTO.0b013e3181d899bb.
7
Tyrosine kinase inhibitors may change the metastatic pattern.酪氨酸激酶抑制剂可能会改变转移模式。
J BUON. 2013 Apr-Jun;18(2):544.
8
Prospective assessment of discontinuation and reinitiation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of everolimus.对厄洛替尼或吉非替尼获得性耐药患者停用和重新开始使用厄洛替尼或吉非替尼，随后加用依维莫司的前瞻性评估。
Clin Cancer Res. 2007 Sep 1;13(17):5150-5. doi: 10.1158/1078-0432.CCR-07-0560.
9
Erlotinib in advanced non-small cell lung cancer: efficacy and safety findings of the global phase IV Tarceva Lung Cancer Survival Treatment study.厄洛替尼治疗晚期非小细胞肺癌的疗效和安全性：全球 IV 期 Tarceva 肺癌生存治疗研究的结果。
J Thorac Oncol. 2010 Oct;5(10):1616-22. doi: 10.1097/JTO.0b013e3181f1c7b0.
10
Autophagy facilitates the EGFR-TKI acquired resistance of non-small-cell lung cancer cells.自噬促进非小细胞肺癌细胞对表皮生长因子受体酪氨酸激酶抑制剂（EGFR-TKI）的获得性耐药。
J Formos Med Assoc. 2014 Mar;113(3):141-2. doi: 10.1016/j.jfma.2012.10.017. Epub 2013 Jan 2.

引用本文的文献

1
Histologic transformation after targeted therapy resistance in driver gene-positive NSCLC: mechanisms and therapeutic challenges.驱动基因阳性非小细胞肺癌靶向治疗耐药后的组织学转化：机制与治疗挑战
Ther Adv Med Oncol. 2025 Sep 1;17:17588359251369038. doi: 10.1177/17588359251369038. eCollection 2025.
2
Targeting ALK in Neuroendocrine Tumors of the Lung.靶向肺神经内分泌肿瘤中的间变性淋巴瘤激酶（ALK）
Front Oncol. 2022 Jun 7;12:911294. doi: 10.3389/fonc.2022.911294. eCollection 2022.
3
Morphologic-Molecular Transformation of Oncogene Addicted Non-Small Cell Lung Cancer.

本文引用的文献

1
Epidermal growth factor receptor tyrosine kinase inhibitor-resistant disease.表皮生长因子受体酪氨酸激酶抑制剂耐药性疾病。
J Clin Oncol. 2013 Mar 10;31(8):1070-80. doi: 10.1200/JCO.2012.43.3912. Epub 2013 Feb 11.
2
Transformation to "high grade" neuroendocrine carcinoma as an acquired drug resistance mechanism in EGFR-mutant lung adenocarcinoma.作为 EGFR 突变型肺腺癌获得性耐药机制的“高级别”神经内分泌癌转化。
Lung Cancer. 2013 Apr;80(1):1-4. doi: 10.1016/j.lungcan.2012.12.019. Epub 2013 Jan 10.
3
Large-cell neuroendocrine carcinoma with epidermal growth factor receptor mutation: possible transformation of lung adenocarcinoma.
癌基因依赖型非小细胞肺癌的形态-分子转化。
Int J Mol Sci. 2022 Apr 9;23(8):4164. doi: 10.3390/ijms23084164.
4
Histological transformation of non-small cell lung cancer: Clinical analysis of nine cases.非小细胞肺癌的组织学转化：9例临床分析
World J Clin Cases. 2021 Jun 26;9(18):4617-4626. doi: 10.12998/wjcc.v9.i18.4617.
5
pathCHEMO, a generalizable computational framework uncovers molecular pathways of chemoresistance in lung adenocarcinoma.pathCHEMO，一个可推广的计算框架，揭示了肺腺癌化疗耐药的分子途径。
Commun Biol. 2019 Sep 6;2:334. doi: 10.1038/s42003-019-0572-6. eCollection 2019.
6
Successful treatment with osimertinib and its subsequent resistance mechanism in a patient with non-small-cell lung cancer harboring acquired EGFR T790M mutation after recovery from AC0010-induced interstitial lung disease.一名非小细胞肺癌患者在从AC0010诱导的间质性肺病恢复后出现获得性EGFR T790M突变，使用奥希替尼成功治疗及其后续耐药机制
Onco Targets Ther. 2019 Jul 10;12:5545-5549. doi: 10.2147/OTT.S204689. eCollection 2019.
7
MYC regulates ductal-neuroendocrine lineage plasticity in pancreatic ductal adenocarcinoma associated with poor outcome and chemoresistance.MYC 调控与不良预后和化疗耐药相关的胰腺导管腺癌中的导管-神经内分泌谱系可塑性。
Nat Commun. 2017 Nov 23;8(1):1728. doi: 10.1038/s41467-017-01967-6.
8
Histological transformation after acquired resistance to epidermal growth factor tyrosine kinase inhibitors.获得性表皮生长因子酪氨酸激酶抑制剂耐药后的组织学转化。
Int J Clin Oncol. 2018 Apr;23(2):235-242. doi: 10.1007/s10147-017-1211-1. Epub 2017 Nov 7.
9
Ginsenoside Rg3 inhibits epithelial-mesenchymal transition (EMT) and invasion of lung cancer by down-regulating FUT4.人参皂苷Rg3通过下调FUT4抑制肺癌的上皮-间质转化（EMT）和侵袭。
Oncotarget. 2016 Jan 12;7(2):1619-32. doi: 10.18632/oncotarget.6451.
10
Inhibition of autophagy potentiates pemetrexed and simvastatin-induced apoptotic cell death in malignant mesothelioma and non-small cell lung cancer cells.自噬抑制增强培美曲塞和辛伐他汀诱导的恶性间皮瘤和非小细胞肺癌细胞凋亡性细胞死亡。
Oncotarget. 2015 Oct 6;6(30):29482-96. doi: 10.18632/oncotarget.5022.
伴有表皮生长因子受体突变的大细胞神经内分泌癌：肺腺癌可能的转化形式
Respirology. 2012 Nov;17(8):1275-7. doi: 10.1111/j.1440-1843.2012.02258.x.
4
Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors.获得性 EGFR 抑制剂耐药的肺癌的基因和组织学演变。
Sci Transl Med. 2011 Mar 23;3(75):75ra26. doi: 10.1126/scitranslmed.3002003.
5
EGFR mutations in small-cell lung cancers in patients who have never smoked.从未吸烟患者的小细胞肺癌中的表皮生长因子受体（EGFR）突变
N Engl J Med. 2006 Jul 13;355(2):213-5. doi: 10.1056/NEJMc053610.